Learn all about the COVID-19 vaccine from Johnson & Johnson

“Built for times like these”

A company in Bern. Janssen Vaccines, part of Johnson & Johnson's Pharmaceuticals business segment. It can draw on over 130 years of experience in the development and production of vaccines. Since January 2020, the company has been working relentlessly on the vaccine to combat COVID-19. This digitally narrated story focuses on the people behind this development.

The journey to the COVID-19 vaccine


All of us are impacted. Hoping for the vaccine. The race began early in January 2020 – and only one year later, now that the values from the third clinical phase are available, Johnson & Johnson has reached the finishing line. An outstanding performance that is still continuing.



130 Years of vaccine know-how


Janssen Vaccines in Bern is working at the forefront of the Corona vaccine. This has a long tradition; the company has been developing vaccines for 130 years.



The quote

“We have already used our AdVac® platform for the development of our Ebola vaccine and saw that this method stimulates different parts of the immune system and activates different protective mechanisms.”


Dirk Redlich, Head Technical Development of Vaccines, Janssen R&D


Read ›

Tested efficacy


The video on the Vox online portal explains how the efficacy of COVID-19 vaccines is tested.


Read ›

Animation video: How vaccines work


Learn how the Johnson & Johnson vaccine based on the adenovirus technology works.


Read ›

A revolutionary idea

Persistent researchers are the keys to vaccine development.





The vaccine against COVID-19 developed by Johnson & Johnson has been granted the following authorisations:


  • 28 February 2021: Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA).
  • 11 March 2021: Conditional authorisation for all 27 EU member states from the Committee of the European Medicines Agency (EMA).
  • 22 March 2021: Swissmedic issues authorisation for a limited period for people aged 18 and over.


Read ›



For further information regarding the
COVID-19 vaccine, please use the
contact details below


Tel: +41 43 547 9884 or 00800 565 4008 8
E-Mail: jgcc_emea@its.jnj.com



Telefon: +41 43 547 9893 oder 0800 475 470

E-Mail: jgcc_emea@its.jnj.com